We look forward to sharing how our diagnostic solutions can enable earlier, more accurate diagnoses - & ultimately improve patient lives.

As Australia’s leading clinical education event for primary healthcare professionals, GPCE is an incredible opportunity to explore the latest innovations, attend engaging workshops, & connect with GPs shaping the future of general practice.

@ProteomicsI is excited to be attending @gpce in Melbourne this Friday–Sunday (July 11–13). Come say hi to the team at booth B107 to learn more about our novel blood tests for predicting diabetic kidney disease and diagnosing oesophageal cancer & endometriosis. #GPCEMelbourne.

𝗗𝗶𝘀𝘂𝗹𝗳𝗶𝗱𝗲 𝗕𝗿𝗶𝗱𝗴𝗲 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗯𝘆 𝟮-𝘁𝗮𝗴.Detect 𝗶𝗻𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗱𝗶𝘀𝘂𝗹𝗳𝗶𝗱𝗲 𝗯𝗼𝗻𝗱𝗶𝗻𝗴 in protein biologics with our 𝗽𝗮𝘁𝗲𝗻𝘁𝗲𝗱 𝗺𝗮𝘀𝘀 𝘀𝗽𝗲𝗰-𝗯𝗮𝘀𝗲𝗱 𝗺𝗲𝘁𝗵𝗼𝗱.#Biosimilars #Disulfide #Biologics.𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲👇

🚀 Tap into Australia’s clinical trial strengths!.Partner with 🇦🇺 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 –.✅ ISO 17025-accredited lab.✅ PK, biomarker, biosimilar services.✅ R&D tax eligible .Delivering results for biotech & pharma worldwide. #AustralianAdvantage.

PromarkerD can predict the onset of the disease up to four years in advance, allowing patients to start treatment on time before kidney disease and loss of kidney function occur.

However, if kidney disease is undetected, kidney damage is often irreversible. 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 are proud to play a role in the fight to reduce the negative impact of chronic kidney disease in type 2 diabetes patients.

An estimated 𝟑𝟑𝟎,𝟎𝟎𝟎 𝗔𝘂𝘀𝘁𝗿𝗮𝗹𝗶𝗮𝗻𝘀 𝗹𝗶𝘃𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗱𝗶𝗮𝗯𝗲𝘁𝗲𝘀 have 𝗰𝗵𝗿𝗼𝗻𝗶𝗰 𝗸𝗶𝗱𝗻𝗲𝘆 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 (Diabetes Australia (2024)). If detected early, treatments and lifestyle changes can slow or halt the progression of the condition.

𝗧𝗵𝗶𝘀 𝘄𝗲𝗲𝗸 𝗺𝗮𝗿𝗸𝘀 #𝗞𝗶𝗱𝗻𝗲𝘆𝗔𝗰𝘁𝗶𝗼𝗻𝗪𝗲𝗲𝗸 𝗵𝗲𝗿𝗲 𝗶𝗻 𝗔𝘂𝘀𝘁𝗿𝗮𝗹𝗶𝗮 (𝗝𝘂𝗹𝘆 𝟏𝘀𝘁 𝘁𝗼 𝗝𝘂𝗹𝘆 𝟕𝘁𝗵).

To all survivors, families, and carers: your courage inspires our ongoing dedication to innovation and hope. Together, we strive for a future where early diagnosis and improved outcomes are within reach for everyone.

Early detection remains a significant challenge, but it is also the key to improving outcomes. At Proteomics International, we are committed to advancing proteomic diagnostics to enable earlier detection and better support for patients.

—𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝘁𝗵𝗼𝘀𝗲 𝗶𝗺𝗽𝗮𝗰𝘁𝗲𝗱 𝗯𝘆 𝗲𝘀𝗼𝗽𝗵𝗮𝗴𝗲𝗮𝗹 𝗰𝗮𝗻𝗰𝗲𝗿. Did you know – Australia is seeing a rising incidence of esophageal adenocarcinoma, especially among people with chronic reflux and obesity.

𝗔𝘀 𝗖𝗮𝗻𝗰𝗲𝗿 𝗦𝘂𝗿𝘃𝗶𝘃𝗼𝗿𝘀 𝗠𝗼𝗻𝘁𝗵 𝗰𝗼𝗺𝗲𝘀 𝘁𝗼 𝗮 𝗰𝗹𝗼𝘀𝗲, 𝘄𝗲 𝗿𝗲𝗳𝗹𝗲𝗰𝘁 𝗼𝗻 𝗮𝗻𝗱 𝗵𝗼𝗻𝗼𝘂𝗿 𝘁𝗵𝗲 𝗶𝗻𝗰𝗿𝗲𝗱𝗶𝗯𝗹𝗲 𝘀𝘁𝗿𝗲𝗻𝗴𝘁𝗵 𝗮𝗻𝗱 𝗿𝗲𝘀𝗶𝗹𝗶𝗲𝗻𝗰𝗲 𝗼𝗳 𝗮𝗹𝗹 𝗰𝗮𝗻𝗰𝗲𝗿 𝘀𝘂𝗿𝘃𝗶𝘃𝗼𝗿𝘀 .

We’re grateful to all who stopped by our booth and a big thank you to the American Diabetes Association for delivering such a powerful and inspiring event.

You can view our full announcements here:.🔗 🔗

- Presentation of the 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗣𝗿𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝗗 𝘁𝗲𝘀𝘁 𝘀𝘆𝘀𝘁𝗲𝗺 as a Late Breaking Abstract, simplified without compromising accuracy.

𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 was proud to showcase two major milestones:.- The 𝗶𝗻𝗶𝘁𝗶𝗮𝗹 𝗨𝗦 𝗹𝗮𝘂𝗻𝗰𝗵 𝗼𝗳 𝗣𝗿𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝗗, our predictive blood test for diabetic kidney disease.

With thousands of delegates from around the globe, the conference brought together leaders in diabetes research, innovation, and clinical care — all united in the mission to improve outcomes for people living with diabetes.

The 85th Scientific Sessions of the 𝗔𝗺𝗲𝗿𝗶𝗰𝗮𝗻 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗶𝗼𝗻 (𝗔𝗗𝗔) in Chicago has wrapped up – and what a fantastic event it was! 🎉💙.hashtag#ADA2025

Simplified without compromising accuracy, the performance results of this next-generation test were selected as a Late Breaking Abstract and presented over the weekend at the (𝗔𝗗𝗔) in Chicago, Illinois.